Promega builds plant to produce regulated products

Published: 29-Aug-2011
Manufacturing Analysis

Including sample preparation systems and reagents

Promega Corporation, based in Madison, Wisconsin, US, has held a ground-breaking ceremony for a new cGMP facility to support business growth and customers who need FDA-regulated molecular biology products. These include sample preparation systems and reagents, which are part of diagnostic and medical tests sold by human diagnostic test providers.

The 260,000ft2 (24,150m2) facility will require an additional 100 people in the next five years. Most of the building will be dedicated to fixed and flexible manufacturing areas. It will also house a customer experience centre for training, laboratory demonstrations and conferences.

‘This building is our next step in expanding our product supply capabilities worldwide,’ said ceo Bill Linton.

Plans include a number of sustainable practices, including geothermal heating and cooling, dark sky compliant lighting, prairie restoration, bio-retention ponds for storm water run off among other sustainable features and construction practices.

Promega Corporation provides solutions and technical support to the life sciences industry. Its 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification.

See more

You may also like

Manufacturing

Promega opens new Shanghai facility

Read more
Provides additional r&d and cGMP manufacturing capabilities

Trending Articles

  1. Preparing for the future of contained oncology drug production Advancements in oncology drug production, containment technologies, and automation have manifestly improved the safety, efficiency, and precision aspects of manufacturing highly potent cancer treatments
  2. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  3. Touchlight named most innovative new manufacturing facility at ISPE 2025 Facility of the Year Awards The company’s restored Victorian waterworks site in Hampton, London, has been recognised for transforming DNA manufacturing with its enzymatic, cell-free dbDNA platform
  4. AstraZeneca to expand Virginia manufacturing facility with $4.5bn investment, creating 3600 jobs AstraZeneca will develop a state-of-the-art manufacturing facility in Albemarle County, Virginia, producing a broader range of medicines, including weight management, metabolic and cancer therapies
  5. AstraZeneca strikes deal with US government to cut drug prices and boost domestic manufacturing AstraZeneca has reached an agreement with the Trump administration to lower medicine costs, pledging $50bn in US manufacturing and R&D investment, whilst safeguarding the nation’s biopharma innovation leadership

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Manufacturing

Promega opens new Shanghai facility

Provides additional r&d and cGMP manufacturing capabilities
Manufacturing

Roquette opens pharmaceutical innovation centre in Brazil

The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing

RHEOFREED: A game-changing innovation in lyophilization technology

Dec Group announces its partnership with Kobelco Eco Solutions, Japan, and presents RHEOFREED®, a revolutionary mixer-type freeze dryer at CPHI Frankfurt 2025
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Manufacturing

Merck breaks ground on $3bn US manufacturing centre

The 400,000 sqft Elkton expansion forms part of Merck’s $70bn US investment plan to bolster domestic pharmaceutical manufacturing and R&D, creating more than 500 new full-time roles
Drug Delivery

Optimised fittings for microfluidic systems

Miniature flat-bottom ports combine convenience and performance for precise fluid control
Manufacturing

FDA US agent services backed by regulatory expertise

Helping medical device companies achieve smooth US market entry
Subscribe now